Core Insights - Protara Therapeutics, Inc. has granted inducement non-qualified stock options and restricted stock units (RSUs) to six newly-hired employees as part of its 2020 Inducement Plan [1][2][3] Employee Compensation - Shane Williams, the new Vice President, Head of Human Resources and Chief People Officer, received 41,000 stock option awards and 20,500 RSU awards with an exercise price of 3.46 per share [3] Vesting Schedule - All option awards vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly thereafter [4] - RSU awards vest over three years, with 33 1/3% vesting on each of the three consecutive anniversaries of the grant date [4] Company Overview - Protara is a clinical-stage biotechnology company focused on developing therapies for cancer and rare diseases, including its lead candidate TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations [5] - The company is conducting ongoing Phase 2 trials for TARA-002 in patients with carcinoma in situ and pediatric patients with lymphatic malformations [5] - Protara is also developing IV Choline Chloride for patients on parenteral nutrition who cannot meet their choline needs through oral or enteral routes [5]
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)